Key result
The superior transseptal approach for mitral valve surgery was not associated with permanent heart rhythm disorders or increased mortality compared to the left atrial approach, though it increased transient nodal rhythm.
Why the study?
A lack of evidence regarding complications with different mitral valve approaches has left exposure choice to surgeon preference rather than comparative safety data.
Does the superior transseptal approach compared to the left-atrial approach increase the incidence of clinically relevant adverse effects in patients undergoing first time elective mitral valve surgery?
Cohort (n=210)
No
Does the superior transseptal approach compared to the left-atrial approach increase the incidence of clinically relevant adverse effects in patients undergoing first time elective mitral valve surgery?
The superior transseptal approach for mitral valve surgery is safe and not associated with an increased risk of permanent heart rhythm disorders or other significant adverse clinical outcomes compared to the left-atrial approach.
May inform mitral exposure choice; level 5 data leaves optimal approach open pending randomized trials.
Background: The lack of evidence with respect to complications with mitral valve approaches leaves the choice of exposure to the surgeon’s preference, basing it on individual experience, speed, ease, and quality of exposure. Methods: Analysis of patients undergoing mitral valve surgery by either a superior transseptal approach or a left-atrial approach between 2006 and 2018. We included first time elective mitral valve procedures, isolated or combined, without a history of rhythm disturbances. We used propensity score matching based on 26 perioperative variables. Primary endpoint was to determine the association between the superior transeptal approach and clinically significant adverse outcomes including arrhythmias, need for permanent pacemaker, cerebrovascular events, and mortalityResults: 652 patients met the inclusion criteria, 391 received the left atrial approach and 261 superior transseptal. After matching, 96 patients were compared with 69, respectively. The distribution of the preoperative and perioperative variables was similar. There was no difference in the incidence of supraventricular tachyarrhythmias and the need for treatment. The incidence of nodal rhythm (p = 0.008) and length of stay in intensive care (p = 0.04) were higher in the superior transseptal group, however the need for permanent pacemaker implantation was the same. Likewise, there was no difference in the need for anticoagulation due to arrhythmia, the incidence of cerebrovascular events or mortality in the postoperative period, and in the long-term follow-up.Conclusion: We did not find an association with permanent heart rhythm disorders or any other significant adverse clinical outcome, therefore we consider that the superior transeptal approach is useful and safe for mitral valve exposure.
No takes yet. Share an insight, caveat, or question.
Obando et al. (2021) conducted a cohort in Mitral valve disease (n=210). Superior transseptal approach vs. Left atrial approach was evaluated on Clinically significant adverse outcomes including arrhythmias, need for permanent pacemaker, cerebrovascular events, and mortality. The superior transseptal approach for mitral valve surgery was not associated with permanent heart rhythm disorders or increased mortality compared to the left atrial approach, though it increased transient nodal rhythm.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: